Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 40
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
A6181114
NCT00428220
2.
Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
NCI, Other
06-248
NCT00438256
3.
Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
Over 18
Other, Pharmaceutical / Industry
00001597
NCT00735306
Last Modified:
3/21/2007
 
First Published:
8/24/2003
4.
Phase II Study of Postoperative Cisplatin, Interferon alfa, Fluorouracil, and Concurrent Radiotherapy in Patients With Previously Resected Pancreatic Adenocarcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
MDA-ID-02040
NCT00068575
First Published:
11/25/2005
5.
Phase II Pilot Study of Neoadjuvant Chemoradiotherapy and Interferon alfa in Patients With Unresectable Locally Advanced Adenocarcinoma of the Pancreas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
UMN-2004LS060
UMN-2743RO, NCT00262951
6.
Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
12095B
NCT00203892
Last Modified:
6/22/2007
 
First Published:
1/6/2006
7.
Phase II Study of an Individualized Drug Treatment Selection Process Based on a Tumor Xenograft Model for Patients With Resectable Pancreatic Adenocarcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
JHOC-J0507
JHOC-05041402, NCT00276744
Last Modified:
6/11/2008
 
First Published:
4/7/2006
8.
Phase II Randomized Study of Neoadjuvant Erlotinib Hydrochloride Followed By Adjuvant Therapy Comprising Capecitabine, Gemcitabine Hydrochloride, and Radiotherapy in Combination With Erlotinib Hydrochloride in Patients With Resectable Stage I or II Adenocarcinoma of the Pancreas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
JHOC-J0534
JHOC-05080408, NCT00313560
9.
Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-Metastatic, Post-Resection Pancreas Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
GI-4000-02
NCT00300950
10.
A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
06-016
NCT00336700
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute